阿哌沙班在心房颤动患者卒中预防中的应用  

Application of apixaban in stroke prevention in patients with atrial fibrillation

作　　者：姜明静[1] 曹立颖[1] 刘宁[2] 

机构地区：[1]兰州大学第一临床医学院,730000 [2]兰州大学第一医院神经内科,730000

出　　处：《国际脑血管病杂志》2012年第7期524-527,共4页International Journal of Cerebrovascular Diseases

摘　　要：心房颤动（atrial fibrillation，AF）是卒中的独立危险因素。AF患者的卒中转归较差，致死率和致残率也较高。对于卒中风险较高的AF患者，需要应用抗凝药。阿哌沙班是近年来新出现的一种口服直接Xa因子抑制药。与华法林等传统抗凝药相比，阿哌沙班在预防AF患者卒中和全身性栓塞方面展现出一定的优势。Atrial fibrillation （AF） is an independent risk factors for stroke. The stroke outcome in patients with AF is poor. The mortality and morbidity were also higher. As for the higher risk of stroke in patients with AF, the application of anticoagulant drugs is needed. Apixaban is an emerging oral direct X a factor inhibitor in recent years. Compared to the traditional anticoagulants, such as warfarin, apixaban shows certain advantages in the prevention of stroke and systemic embolism in patients with AF.

关 键 词：心房颤动 卒中 抗凝药 因子Xa 阿哌沙班 华法林 

分 类 号：R541.75[医药卫生—心血管疾病]